Difficulty: Medium
Average Score: 65%
Practice
Which of the following opioid analgesics is a strong kappa receptor agonist and a mu receptor antagonist?
Correct answer
C
Rationale
In the context of Lifespan Pharmacology, understanding the mechanisms of action of opioid analgesics is crucial for safe and effective pain management. The correct answer to the question is option C) Nalbuphine.
Nalbuphine is a unique opioid analgesic that acts as a strong kappa receptor agonist and a mu receptor antagonist. This dual mechanism of action gives it a distinct profile compared to other opioids, making it a valuable option for pain management in certain situations. By activating kappa receptors and blocking mu receptors, nalbuphine provides analgesia with a reduced risk of respiratory depression and addiction potential.
Now, let's analyze why the other options are incorrect:
A) Naltrexone is an opioid receptor antagonist, primarily targeting mu receptors. It is used to treat opioid addiction and overdose, not as an analgesic.
B) Methadone is a synthetic opioid agonist primarily acting on mu receptors. It is commonly used in opioid addiction treatment and chronic pain management.
D) Buprenorphine is a partial mu receptor agonist and a kappa receptor antagonist. It is often used in opioid addiction treatment and chronic pain management due to its unique pharmacological profile.
Understanding the specific pharmacological actions of different opioid analgesics is essential for healthcare professionals to make informed decisions regarding pain management in patients across the lifespan. This knowledge helps in selecting the most appropriate opioid based on the patient's condition, pain intensity, and risk factors for adverse effects.
Nalbuphine is a unique opioid analgesic that acts as a strong kappa receptor agonist and a mu receptor antagonist. This dual mechanism of action gives it a distinct profile compared to other opioids, making it a valuable option for pain management in certain situations. By activating kappa receptors and blocking mu receptors, nalbuphine provides analgesia with a reduced risk of respiratory depression and addiction potential.
Now, let's analyze why the other options are incorrect:
A) Naltrexone is an opioid receptor antagonist, primarily targeting mu receptors. It is used to treat opioid addiction and overdose, not as an analgesic.
B) Methadone is a synthetic opioid agonist primarily acting on mu receptors. It is commonly used in opioid addiction treatment and chronic pain management.
D) Buprenorphine is a partial mu receptor agonist and a kappa receptor antagonist. It is often used in opioid addiction treatment and chronic pain management due to its unique pharmacological profile.
Understanding the specific pharmacological actions of different opioid analgesics is essential for healthcare professionals to make informed decisions regarding pain management in patients across the lifespan. This knowledge helps in selecting the most appropriate opioid based on the patient's condition, pain intensity, and risk factors for adverse effects.